These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 30498879)

  • 21. [Treatment of acute and recurrent Clostridium difficile infections : What is new?].
    von Braun A; Lübbert C
    Internist (Berl); 2018 May; 59(5):505-513. PubMed ID: 29536125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention and treatment of
    Eliakim-Raz N; Bishara J
    Hum Vaccin Immunother; 2019; 15(6):1453-1456. PubMed ID: 29781761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
    Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
    Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for Clostridium difficile infections in Baranya County, Southern Hungary.
    Vigvári S; Sipos D; Kappéter Á; Feiszt Z; Kovács B; Péterfi Z
    Acta Microbiol Immunol Hung; 2018 Jun; 65(2):183-192. PubMed ID: 29651860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal microbiota transplantation for the treatment of Clostridium difficile infection.
    Rao K; Safdar N
    J Hosp Med; 2016 Jan; 11(1):56-61. PubMed ID: 26344412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
    Allegretti JR; Kao D; Phelps E; Roach B; Smith J; Ganapini VC; Kassam Z; Xu H; Fischer M
    Dig Dis Sci; 2019 Jun; 64(6):1668-1671. PubMed ID: 30632052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current treatment and epidemiology of Clostridium difficile infections].
    Dinh A; Bouchand F; Le Monnier A
    Rev Med Interne; 2015 Sep; 36(9):596-602. PubMed ID: 25772664
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Asempa TE; Nicolau DP
    Clin Interv Aging; 2017; 12():1799-1809. PubMed ID: 29123385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and management of Clostridium difficile infection.
    Korman TM
    Semin Respir Crit Care Med; 2015 Feb; 36(1):31-43. PubMed ID: 25643269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential for emerging therapeutic options for Clostridium difficile infection.
    Mathur H; Rea MC; Cotter PD; Ross RP; Hill C
    Gut Microbes; 2014; 5(6):696-710. PubMed ID: 25564777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS
    Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical review of Clostridium difficile infection: an update on treatment and prevention.
    Daniels LM; Kufel WD
    Expert Opin Pharmacother; 2018 Nov; 19(16):1759-1769. PubMed ID: 30220230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microbiologic factors affecting Clostridium difficile recurrence.
    Chilton CH; Pickering DS; Freeman J
    Clin Microbiol Infect; 2018 May; 24(5):476-482. PubMed ID: 29208562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.
    Aroniadis OC; Brandt LJ; Greenberg A; Borody T; Kelly CR; Mellow M; Surawicz C; Cagle L; Neshatian L; Stollman N; Giovanelli A; Ray A; Smith R
    J Clin Gastroenterol; 2016; 50(5):398-402. PubMed ID: 26125460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Faecal transplantation for the treatment of Clostridium difficile infection: a review.
    McCune VL; Struthers JK; Hawkey PM
    Int J Antimicrob Agents; 2014 Mar; 43(3):201-6. PubMed ID: 24636428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
    Konijeti GG; Sauk J; Shrime MG; Gupta M; Ananthakrishnan AN
    Clin Infect Dis; 2014 Jun; 58(11):1507-14. PubMed ID: 24692533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current advances related to Clostridium difficile infection.
    Kim YG; Jang BI
    Indian J Med Res; 2015 Feb; 141(2):172-4. PubMed ID: 25900952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Therapy of Severe Pseudomembranous Clostridium difficile Colitis Using a Combination of Fecal Microbiota Therapy and Fidaxomicin.
    Konturek PC; Haziri D; Helfritzsch H; Hess T; Harsch IA
    Med Princ Pract; 2017; 26(2):182-184. PubMed ID: 27978522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.